Akero Therapeutics stock crashed 65% on Tuesday: what happened?

October 10, 2023 08:12 AM PDT | By Invezz

Akero Therapeutics stock crashed 65% on Tuesday: what happened? — Image source: Invezz

Akero Therapeutics’ EFX failed a key test

On Tuesday, the biotech firm said its Efruxifermin did not perform significantly better than placebo in the said clinical trial.

A high dose of EFX improved live fibrosis by at least one-stage in 24% of the patients after 36 weeks. Similar results were observed in 14% of the patients on placebo as well.

But Akero Therapeutics remains convinced that its treatment will show additional improvements at 96 weeks. Earlier this year, the Nasdaq-listed firm said it had sufficient liquidity to fund operations through 2026.

Akero Therapeutics stock is now down more than 70% versus its year-to-date high in June.

How it started: $AKRO UBS Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $83

How it's going: pic.twitter.com/Ui1mXrSHDi
— Arete Trading (@AreteTrading) October 10, 2023

EFX significantly boosted rate of NASH resolution

Akero Therapeutics did confirm, though, that about 60% of patients on Efruxifermin in the clinical trial had NASH resolution in 36 weeks.

Only 26% of the patients on placebo, in comparison, showed similar results. Stephen Harrison – the Principal Investigator of SYMMETRY said in a press release today:

The results are the strongest data set reported to date in a placebo-controlled trial in the difficult-to-treat population of patients with cirrhosis due to NASH.

This update arrives months after the biotechnology company raised about $220 million via a direct offering of more than 5.0 million shares at $42 each. Heading into Tuesday, Wall Street had a consensus “buy” rating on Akero Therapeutics stock.

The post Akero Therapeutics stock crashed 65% on Tuesday: what happened? appeared first on Invezz.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.